BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 9690659)

  • 1. Neuroendocrine cells in benign and malignant prostate tissue: morphogenesis, proliferation, and androgen receptor status.
    Bonkhoff H
    Prostate Suppl; 1998; 8():18-22. PubMed ID: 9690659
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differentiation pathways and histogenetic aspects of normal and abnormal prostatic growth: a stem cell model.
    Bonkhoff H; Remberger K
    Prostate; 1996 Feb; 28(2):98-106. PubMed ID: 8604398
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuroendocrine differentiation in human prostate cancer. Morphogenesis, proliferation and androgen receptor status.
    Bonkhoff H
    Ann Oncol; 2001; 12 Suppl 2():S141-4. PubMed ID: 11762342
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuroendocrine cells in human prostate over-express the anti-apoptosis protein survivin.
    Xing N; Qian J; Bostwick D; Bergstralh E; Young CY
    Prostate; 2001 Jun; 48(1):7-15. PubMed ID: 11391682
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Androgen deprivation induces human prostate epithelial neuroendocrine differentiation of androgen-sensitive LNCaP cells.
    Yuan TC; Veeramani S; Lin FF; Kondrikou D; Zelivianski S; Igawa T; Karan D; Batra SK; Lin MF
    Endocr Relat Cancer; 2006 Mar; 13(1):151-67. PubMed ID: 16601285
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The androgen receptor status of neuroendocrine cells in human benign and malignant prostatic tissue.
    Nakada SY; di Sant'Agnese PA; Moynes RA; Hiipakka RA; Liao S; Cockett AT; Abrahamsson PA
    Cancer Res; 1993 May; 53(9):1967-70. PubMed ID: 8481896
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Androgen deprivation of the PC-310 [correction of prohormone convertase-310] human prostate cancer model system induces neuroendocrine differentiation.
    Jongsma J; Oomen MH; Noordzij MA; Van Weerden WM; Martens GJ; van der Kwast TH; Schröder FH; van Steenbrugge GJ
    Cancer Res; 2000 Feb; 60(3):741-8. PubMed ID: 10676662
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The neuroendocrine phenotype in prostate cancer: basic and clinical aspects.
    Mosca A; Berruti A; Russo L; Torta M; Dogliotti L
    J Endocrinol Invest; 2005; 28(11 Suppl International):141-5. PubMed ID: 16625864
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cell kinetics of prostate exocrine and neuroendocrine epithelium and their differential interrelationship: new perspectives.
    Xue Y; Smedts F; Verhofstad A; Debruyne F; de la Rosette J; Schalken J
    Prostate Suppl; 1998; 8():62-73. PubMed ID: 9690665
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Localization of immunoreactive HIF-1alpha and HIF-2alpha in neuroendocrine cells of both benign and malignant prostate glands.
    Monsef N; Helczynski L; Lundwall A; Påhlman S;
    Prostate; 2007 Aug; 67(11):1219-29. PubMed ID: 17562539
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuroendocrine-like prostate cancer cells: neuroendocrine transdifferentiation of prostate adenocarcinoma cells.
    Yuan TC; Veeramani S; Lin MF
    Endocr Relat Cancer; 2007 Sep; 14(3):531-47. PubMed ID: 17914087
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comprehensive expression analysis of L-dopa decarboxylase and established neuroendocrine markers in neoadjuvant hormone-treated versus varying Gleason grade prostate tumors.
    Wafa LA; Palmer J; Fazli L; Hurtado-Coll A; Bell RH; Nelson CC; Gleave ME; Cox ME; Rennie PS
    Hum Pathol; 2007 Jan; 38(1):161-70. PubMed ID: 16997353
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interleukin-6 undergoes transition from growth inhibitor associated with neuroendocrine differentiation to stimulator accompanied by androgen receptor activation during LNCaP prostate cancer cell progression.
    Lee SO; Chun JY; Nadiminty N; Lou W; Gao AC
    Prostate; 2007 May; 67(7):764-73. PubMed ID: 17373716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [New aspects in histogenesis of hyperplasia and cancers of the prostate].
    Bonkhoff H; Remberger K
    Verh Dtsch Ges Pathol; 1993; 77():31-9. PubMed ID: 7511302
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acquisition of neuroendocrine characteristics by prostate tumor cells is reversible: implications for prostate cancer progression.
    Cox ME; Deeble PD; Lakhani S; Parsons SJ
    Cancer Res; 1999 Aug; 59(15):3821-30. PubMed ID: 10447001
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The influence of neuroendocrine differentiation on the growth and androgen receptor expression of prostate carcinoma cells].
    Song Y; Wu G; Xin DQ; Na YQ
    Zhonghua Wai Ke Za Zhi; 2004 Dec; 42(23):1453-6. PubMed ID: 15733464
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation and clinical value of neuroendocrine differentiation in human prostatic tumors.
    Cussenot O; Villette JM; Cochand-Priollet B; Berthon P
    Prostate Suppl; 1998; 8():43-51. PubMed ID: 9690663
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Apoptosis resistance of neuroendocrine phenotypes in prostatic adenocarcinoma.
    Fixemer T; Remberger K; Bonkhoff H
    Prostate; 2002 Oct; 53(2):118-23. PubMed ID: 12242726
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of neuroendocrine staining and androgen receptor expression in incidental prostatic adenocarcinoma: prognostic implications.
    Theodoropoulos VE; Tsigka A; Mihalopoulou A; Tsoukala V; Lazaris AC; Patsouris E; Ghikonti I
    Urology; 2005 Oct; 66(4):897-902. PubMed ID: 16230178
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interferon-gamma induces neuroendocrine-like differentiation of human prostate basal-epithelial cells.
    Untergasser G; Plas E; Pfister G; Heinrich E; Berger P
    Prostate; 2005 Sep; 64(4):419-29. PubMed ID: 15800938
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.